Payment overview · 2025
General Payments
$435.66
20 reported records · 11 companies
Healthcare provider profile · identity verified
Sandra M Cornine, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · OKEECHOBEE, FL · NPI 1538813324
Verified facts
What the public records show
CMS Open Payments records show Sandra M Cornine, APRN received $435.66 in general payments during 2025 across 20 reported records.
Supernus Pharmaceuticals, Inc. accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $148.58 | 34.1% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $49.64 | 11.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.14 | 11.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.51 | 9.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.10 | 6.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $23.59 | 5.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.62 | 4.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.08 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.60 | 4.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.59 | 4.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.21 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $435.66 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $148.58 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $49.64 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.14 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.10 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 63 |
| Losartan Potassium | Losartan Potassium | 149 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 148 | 53 |
| Metformin Hcl | Metformin Hcl | 140 | 52 |
| Omeprazole | Omeprazole | 132 | 51 |
| Lisinopril | Lisinopril | 127 | 43 |
| Alprazolam | Alprazolam | 121 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 109 | 36 |
| Buspirone Hcl | Buspirone Hcl | 105 | 28 |
| Prednisone | Prednisone | 101 | 75 |
| Gabapentin | Gabapentin | 92 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 36 |
| Chlorthalidone | Chlorthalidone | 84 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 20 |
| Carbamazepine | Carbamazepine | 64 | 16 |
| Potassium Chloride | Potassium Chloride | 62 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 19 |
| Torsemide | Torsemide | 56 | 21 |
| Glimepiride | Glimepiride | 54 | 19 |
| Tramadol Hcl | Tramadol Hcl | 52 | 19 |
| Olanzapine | Olanzapine | 50 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 42 |
| Trazodone Hcl | Trazodone Hcl | 48 | 16 |
| Clonidine Hcl | Clonidine Hcl | 47 | 19 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Ondansetron Odt | Ondansetron | 44 | 26 |
| Ezetimibe | Ezetimibe | 42 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 14 |
| Eliquis | Apixaban | 39 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 36 |
| Carvedilol | Carvedilol | 36 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | 13 |
| Furosemide | Furosemide | 34 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 12 |
| Spironolactone | Spironolactone | 33 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 26 |
| Simvastatin | Simvastatin | 32 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Meloxicam | Meloxicam | 30 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | 13 |
| Ibuprofen | Ibuprofen | 29 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 21 |
| Ozempic | Semaglutide | 29 | 12 |
| Allopurinol | Allopurinol | 28 | 11 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 12 |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | 12 |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 22 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 23 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Nystatin | Nystatin | 16 | 11 |
| Atomoxetine Hcl | Atomoxetine Hcl | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Thiothixene | Thiothixene | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $435.66 · 20 records | Supernus Pharmaceuticals, Inc. | ABRYSVO, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Korlym, Ozempic, PREVNAR 20, Qelbree, TZIELD, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error